ASTRAZENECA

ASTRAZENECA
Headquarters Country
UK
Headquarters Sub Region
Northern Europe
World Rank (Jan-07-2022)
71
Market Value (Jan-07-2022)
178.12 Billion USD
World Rank (Sep-01-2021)
69
Market Cap (Sep-01-2021)
181.45 Billion USD
World Rank (Jan-01-2021)
93
Market Value (Jan-01-2021)
130.99 Billion USD
World Rank (Jan-2020)
72
Market Value (Jan 1st 2020)
135.30 Billion USD
Annual Revenue in USD
37,417 Million USD
Annual Net Income in USD
112 Million USD
Annual Results for Year Ending
Dec-2021
Total Assets in USD
105,360 Million USD
Total Liabilities in USD
66,095 Million USD
Total Equity in USD
39,268 Million USD
Balance Sheet Summary for Period ending
Dec-2021
Headquarters Region / City
Cambridge
Stock Category
FTSE 100
S&P EUROPE 350
Rank in Country (Jan-2020)
Rank in UK in 2020 is 4
Rank in Country (Jan-2021)
Company Rank in UK in 2021 is 4
ISIN Code:
GB0009895292
Company Business
Healthcare
Pharmaceutical
Biopharmaceutical
Biotechnology
HealthCare Products
Technology
Number of Employees
83,100
Employee Count as on Date
As on 2021
Headquarters Continent
Europe
Chairman
Leif Johansson
CEO:
Pascal Soriot
Founded Year
1999
Stock Exchange
NYSE
Stockholm
LSE
Yahoo @ NYSE
Wikipedia
Twitter
Bloomberg
Company Website:
Astrazeneca - Healthcare and Pharamaceutical Company
Business Sector:
Top Healthcare Companies in UK
Top Technology Companies in UK
Top Healthcare Companies in Europe
Top Technology Companies in Europe
Top Pharmaceutical Companies in Europe
About Company Business:

ASTRAZENECA is UK Based Pharmaceutical and Bio-Technology Company. In the fight against COVID-19,Astrazeneca is one among World Top 5 Companies which is in advanced phase of Covid-19 testing in collaboration with the University of Oxford and are launching Phase III trials. Headquarters is in UK.

AstraZeneca has annual revenue was 37,417 million USD for year ending Dec-2021 when compared to with 26,617 million USD as on 2020.

AstraZeneca Annual Product Sales was 36,541 million USD for year ending Dec-2021 when compared with 25,890 million USD for year ending Dec-2020.

For year ending Dec-2021, operating income was 1.056 Million USD.

AstraZeneca has 83,100 employees as on 2021 when compared to with 76,100 employees as on 2020 and 70,600 employees as on 2019.

AstraZeneca has total assets are 105,363 million USD as on Dec-2021 when compared to 66,729 million USD as on Dec-2020.

ASTRAZENECA Product Sales split by Disease Area for year ending Dec-2021

  • Oncology contributed 36% and annual revenue contributed is 13,048 million USD.
  • BioPharmaceuticals contributed 38% and annual  revenue contributed is 8,02 million USD.
  • Rare Disease contributed 8%  annual revenue contributed is 3,070 million USD.
  • Other Medicines contributed 17%  annual revenue contributed is 2,367 million USD.
  • Covid-19 contributed 11% annual revenue contributed is 4,002 million USD.
  • Respiratory & Immunology contributed 17% annual revenue contributed is 6,034 million USD.

ASTRAZENECA Product Sales split of 36,541 Million USD by Disease Area for year ending Dec-2021

  • 12,161 Million USD from Emerging Markets
  • 12,000 Million USD from USA.
  • 7,604 Million USD from Europe.
  • From the rest of the World, it is 4,776 Million USD

 

Facts About Company

Astrazeneca company acquired Alexion Pharmaceuticals for 39 Billion USD in 2020.

As on 2021, Astrazeneca has 83,100 employees and out of that

  • 15,900 employees are from USA.
  • 8,800 employees are from UK
  • 20,600 employees are from China
  • 6,900 employees are from Sweden
  • 11,400 employees are from Other Europe has 
  • 7,100 employees are from Other Asia Pacific
  • 1,100 employees are from Canada and 1,800 employees are from Middle East and Africa and 1,600 employees are from Russia and 3,400 employees are from Japan and 1,000 employees are from Australia and New Zealand
Annual Revenue
ASTRAZENECA Annual Revenues for December-2020 ending is 26.21 Billion USD
Annual Operating Income
3.69 Billion USD for Year ending December-2020
Annual Net Income
ASTRAZENECA Annual Net Income for December-2020 ending is 3.19 Billion USD
Total Current Assets
15,563 Million USD as on Dec 2019
Total Assets
66.73 Billion USD for Year ending December-2020
Total Current Liabilities
18,117 Million USD as on Dec 2019
Total Liabilities
51.09 Billion USD for Year ending December-2020
Total Equity
15.64 Billion USD for Year ending December-2020
Annual Results Summary:

AstraZeneca PLC - Annual Results - Revenue and Net Profit - in Million USD:

Year - Ending Revenue Operating Income Net Profit EPS (USD)
Dec-2021 37,417 1,056 112 0.08
Dec-2020 26,217 3,694 3,196 2.43
Dec-2019 24,384 1,702 1,335 0.52
Dec-2018 22,090 1,510 2,155 0.85
Dec-2017 22,465 2,292 3,001 1.19
Balance Sheet Summary

AstraZeneca PLC - Balance Sheet Summary - in Million USD:

Astrazeneca Total Assets as on September-2021 was 107,221 Million USD.

Astrazeneca Total Liabilities as on September-2021 was 67,309 Million USD.

Astrazeneca Total Equity as on September-2021 was 39,912 Million USD.

Quarterly Results Summary:

AstraZeneca PLC - Quarterly Results - Revenue and Net Profit - in Million USD:

Quarter - Ending Revenue Net Profit
Jun-2022 10,771 360
Mar-2022 11,390 386
Dec-2021 12,011 -292 (Loss)
Sep-2021 9,866 -1,652
Jun-2021 8,220 550
Mar-2021 7,320 1,561
Dec-2020 7,410 1,012
Sep-2020 6,578 651
Jun-2020 6,275 837
Mar-2020 6,354 780
Dec-2019 6,664 313
Sep-2019 6,406 299
Jun-2019 5,823 130
Mar-2019 5,491 593

Comments

Oxford Vaccine Trials again resumed by Astrazeneca

Oxford Vaccine Trials again resumed by Astrazeneca after UK Regulatory Authorities had given permission to go ahead with trials. Post one person undergoing trials had fallen ill, Astrazeneca temporarily paused trials of Oxford Vaccine.

Then again after review, as UK health regulatory authorities had given permission to go ahead with trials, again Oxford Vaccine Trials started.

Russia vaccine and Oxford vaccine are two vaccines related to Covid-19, that are in most advance stages of testing.

Sun, 13/09/2020 - 14:51

Share it on Social Media